Latest Emergent BioSolutions News & Updates

See the latest news and media coverage for Emergent. We track all announcements, press releases, and industry mentions in real time, all in one place.

Emergent BioSolutions (Emergent)

Specialty life sciences company focused on public health preparedness

emergentbiosolutions.com

Headquarters: Gaithersburg, United States
Founded year: 1998
Company type: Public company
Number of employees: 500–1,400
Industry: Pharmaceuticals

Last updated Today

Latest news about Emergent BioSolutions (Emergent)

In short: Emergent BioSolutions refinanced debt, won mpox and Narcan approvals, and named a new CEO amid legal settlements and a Q4 EPS miss.

Company announcements

8 March 2024 Emergent

Emergent furloughs 130 employees due to vaccine procurement uncertainty

The company implements the furlough program in Lansing beginning March 9 amid unclear federal funding and timing for its CYFENDUS anthrax vaccine.

18 January 2024 Emergent

Emergent BioSolutions extends NARCAN shelf life to four years

The FDA acknowledged the extension based on stability data, reducing waste and supporting opioid crisis response efforts starting early 2024.

13 December 2023 Emergent

Emergent BioSolutions Receives Canadian Approvals for Smallpox Countermeasures

ACAM2000 vaccine and TEMBEXA drug gain Health Canada compliance. These products support public health preparedness against smallpox bioterrorism threats.

5 October 2023 Emergent

Emergent resolves FDA issues at Camden facility

The company received a Warning Letter close-out and a closed inspection status from the FDA for its manufacturing site.

Media coverage

Yesterday BioPharm International

Emergent BioSolutions Hit with FDA Form 483 | BioPharm International

FDA inspectors identified nine conditions at Emergent BioSolutions’ Maryland vaccine manufacturing facility that could lead to product quality issues including unsanitary conditions, inadequate facility size...

August 18 The Globe and Mail

Emergent BioSolutions Secures New BARDA Anthrax Contract

Detailed price information for Emergent Biosolutions (EBS-N) from The Globe and Mail including charting and trades.

August 11 Business Wire

Securities Fraud Investigation Into Emergent BioSolutions Inc. (EBS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz announces an investigation of Emergent BioSolutions Inc. (“Emergent BioSolutions” or the “Company”) (NYSE: EBS) on behalf of...

August 6 American City Business Journals

Emergent BioSolutions laying off dozens, shedding real estate as Narcan competition strains profits - Washington Business Journal

Emergent BioSolutions cuts 93 jobs and sheds real estate as Narcan sales decline amid competition in the opioid-reversal drug market.

Never miss news about Emergent

Track Emergent and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Emergent competitors & trending companies

Browse news for competitors to Emergent and other trending companies.